Abstracts Archive - Page 2210 of 2425 - ACR Meeting Abstracts

Abstract Number: 587 • 2013 ACR/ARHP Annual Meeting
Low-Dose Aspirin Has An Anti-Platelet Effect In Systemic Lupus Erythematosus
Michelle Petri¹, Laurence S. Magder² and Thomas Kickler¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: Thrombosis is increased in SLE patients, with and without antiphospholipid antibodies. Aspirin and hydroxychloroquine are thought to have anti-platelet effects. We determined whether these…
Abstract Number: 588 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Rituximab In Patients With Refractory Lupus Nephritis, a Post-Hoc Analysis From Phase II Trial In Japan
Yoshiya Tanaka¹, Kazuhiko Yamamoto², Tsutomu Takeuchi³, Nobuyuki Miyasaka⁴, Takayuki Sumida⁵, Tsuneyo Mimori⁶, Takao Koike⁷ and Kazuhiro Endo⁸, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Department of Allergy and Rhaumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁷Rheumatology, NTT Sapporo Medical Center, Sapporo, Japan, ⁸Clinical Development, Zenyaku Kogyo Co., Ltd., Tokyo, Japan
Background/Purpose: B-cell depletion therapy by rituximab has been reported to be useful for treatment of lupus nephritis (LN) in many observational uncontrolled studies, however, placebo-controlled…
Abstract Number: 589 • 2013 ACR/ARHP Annual Meeting
A Survey Of Physician and Patient Satisfaction With Control Of Systemic Lupus Erythematosus and Lupus Nephritis
Neelufar Mozaffarian¹, Steve Lobosco² and Adam Roughley², ¹AbbVie, North Chicago, IL, ²Adelphi Real World Ltd., Macclesfield, United Kingdom
Background/Purpose: Patient satisfaction with disease control is an important component of overall health and well-being. Current treatment options for systemic lupus erythematosus (SLE) ±lupus nephritis…
Abstract Number: 590 • 2013 ACR/ARHP Annual Meeting
Candidate Urinary Biomarkers May Predict The Future Development Of Renal Functional Loss With Lupus Nephritis In Children and Adults
Khalid Abulaban¹, Brad H. Rovin², Shannen Nelson³, Huijuan Song⁴, Paul Kimmel⁵, John Kusek⁶, Harold Feldman⁷, Vasan Ramachandran⁸, Michael Bennett⁹, Jun Ying¹⁰ and Hermine Brunner¹¹, ¹Pediatric Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Division of Nephrology, Ohio State University Medical Center, Columbus, OH, ³Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ⁴Ohio State University Medical Center, Columbus, OH, ⁵DIVISION OF KIDNEY, UROLOGIC, & HEMATOLOGIC DISEASES, NIDDK, National Institutes of Health, Bethesda, MD, ⁶NIDDK, National Institutes of Health, Bethesda, MD, ⁷The University of Pennsylvania, Philadelphia, PA, ⁸Section of Preventive Medicine and Epidemiology, Boston University School of Medicine, Boston, MA, ⁹Nephrology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰Medicine-Internal Medicine-General Medicine, University of Cincinnati, Cincinnati, OH, ¹¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Lupus nephritis(LN) is frequently associated with a poor long-term prognosis. Current non-invasive blood and urine tests do not reliably predict the course of LN.…
Abstract Number: 592 • 2013 ACR/ARHP Annual Meeting
Analysis Of Relationship Between Clinical Manifestations and Autoantibody Profile In ISN/RPS Class V Lupus Nephritis
Masanori Hanaoka, Takahisa Gono, Yasushi Kawaguchi, Hisashi Yamanaka, Yasuhiro Katsumata, Kae Takagi, Hirotaka Kaneko, Hisae Ichida, Yuko Ota, Hidenaga Kawasumi, Sayumi Baba, Yuko Okamoto and Sayuri Kataoka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Clinical manifestations, pathohistology and treatment strategy are different between International Society of Nephrology/Renal Pathology Society (ISN /RPS) class III/IV and class V Lupus Nephritis…
Abstract Number: 593 • 2013 ACR/ARHP Annual Meeting
Urinary Prostaglandin D Synthetase As a Biomarker Of Lupus Nephritis Activity: One Year Longitudinal Study
Ranjan Gupta¹, Akhilesh Yadav¹, Ramnath Misra² and Amita Aggarwal², ¹Department of Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Proteomic analysis of urine samples, from patients with active lupus nephritis (LN)1-2 and from animal model of LN3 has led to identification of Prostaglandin…
Abstract Number: 594 • 2013 ACR/ARHP Annual Meeting
Renal Biopsy Findings In Lupus Patient With Insignificant Proteinuria : Relation To Disease Activity and Clinical Manifestations
Abdel Azeim M. Al-Hefny¹, Samah El-bakry², Sameh A. Mobasher³, Ola H. Nada⁴ and Nouran Abaza⁵, ¹Department of Internal Medicine and Rheumatology, Professor of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, Cairo, Egypt, ²Department of Internal Medicine and Rheumatology, Assistant professor of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, ³Department of Internal Medicine and Rheumatology, Lecturer of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, ⁴Department of Pathology, Faculty of Medicine, Ain Shams University, Lecturer of Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt, ⁵Physical medicine, Rheumatology and Rehabilitation, Lecturer of Physical medicine, Rheumatology and Rehabilitation, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Background/Purpose: Lupus nephritis (LN) remains one of the most serious manifestations of systemic lupus erythematosus (SLE) and is associated with significant morbidity and mortality. Early…
Abstract Number: 595 • 2013 ACR/ARHP Annual Meeting
Anemic Hypoxia Is Associated With Pulmonary Arterial Hypertension In Patients With Systemic Lupus Erythematosus
Ki-Jo Kim¹, In-Woon Baek², Chong-Hyeun Yoon³, Jin-Jung Choi⁴, Wan-Uk Kim² and Chul-Soo Cho⁵, ¹Internal Medicine, St. Vincent’s Hospital, The Catholic University of Korea, Suwon, South Korea, ²Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, South Korea, ⁴Internal Medicine, CHA University Hospital, Seongnam, South Korea, ⁵Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Pulmonary arterial hypertension (PAH) is a serious and often fatal complication of systemic lupus erythematosus (SLE), but its pathogenesis is still unclear. Hypoxia-induced pulmonary…
Abstract Number: 596 • 2013 ACR/ARHP Annual Meeting
Extended Follow-Up Of a Investigator-Initiated trial Comparing Two Sequential Induction and Maintenance Treatment Regimens For Proliferative Lupus Nephritis Based Either On Cyclophosphamide Or Cyclosporine A
Jakub Zavada¹, Satu Pesickova², Romana Rysava³, Pavel Horak⁴, Zbynek Hrncir⁵, Jozef Rovensky⁶, Jozef Lukac⁷, Jirina Vitova⁸, Jana Böhmova⁹, Marta Olejarova¹⁰, Dana Tegzova¹¹ and Vladimir Tesar¹², ¹Charles University, Prague, Czech Republic, ²Nephrology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic, ³General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴3rd Department of Internal Medicine, 3rd Department of Internal Medicine University Hospital Olomouc, Olomouc, Czech Republic, ⁵2nd Department of Medicine, Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic, ⁶PRINTO, Genoa, Italy, ⁷National Institute of Rheumatology, Piestany, Slovakia, ⁸Hospital, Ceske Budejovice, Czech Republic, ⁹Faculty Hospital St. Anna, Brno, Czech Republic, ¹⁰Institute of Rheumatology, Prague, Prague, Czech Republic, ¹¹Institute of Rheumatology, Prague, Czech Republic, ¹²Department of Nephrology, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: In the investigator-initiated CYLOFA-LUNE trial we tested the hypothesis that immunosuppressive regimen based on Cyclosporine A (CYA) may have similar efficacy but greater safety than…
Abstract Number: 597 • 2013 ACR/ARHP Annual Meeting
Low Complement (C3), Male Gender and Methotrexate Use Are Associated With Noncalcified Plaque In Systemic Lupus Erythematosus
Adnan Kiani¹, Armin Zadeh², Jens Vogel-Claussen¹, Joao Lima², Laurence S. Magder³ and Michelle Petri¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD
Background/Purpose: New technology (CTA) can measure non-calcified coronary plaque (NCP), which is highly unstable and prone to rupture. We quantified NCP in SLE and determined…
Abstract Number: 599 • 2013 ACR/ARHP Annual Meeting
Association Between Serum Leptin and Adiponectin Levels With The Severity Of Proteinuria In Lupus Nephritis
Valeria Diaz-Rizo¹, Nicte Selene Fajardo-Robledo², Alan Joel Ruiz-Padilla², Dalia Sanchez-Mosco³, Tania Marlene Rodriguez-Hernandez⁴, Xochitl Trujillo⁵, Miguel Huerta⁵, Monica Vazquez del Mercado⁶, Laura Gonzalez-Lopez⁴ and Jorge Ivan Gamez-Nava⁷, ¹Doctorado en Ciencias Médicas, Centro Universitario de Investigación Biomédica, Universidad de Colima; UMAE, Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara, Jalisco, Mexico, ²Fisiología, Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico, ³Centro Universitario de Investigación Biomédica, Universidad de Colima; Hospital General Regional 110 IMSS, Guadalajara, Jalisco, Mexico, ⁴Departamento de Medicina Interna/Rheumatología, Hospital General Regional 110, Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco, Mexico, ⁵Centro Universitario de Investigación Biomédica, Universidad de Colima, Colima, Mexico, ⁶Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, ⁷UMAE, Centro Médico Nacional de Occidente, IMSS; Doctorado en Farmacología, Universidad de Guadalajara, Jalisco, Mexico
Background/Purpose: To identify the association between serum leptin and adiponectin levels and proteinuria secondary to lupus nephritis in women with systemic lupus erythematosus (SLE). Methods:…
Abstract Number: 600 • 2013 ACR/ARHP Annual Meeting
Factors Associated With Long-Term Renal Function Deterioration In Lupus Nephritis Treated Initially With Combined Prednisolone and Mycophenolate Mofetil (MMF) Or Tacrolimus (Tac)
Chi Chiu Mok¹, Chi Hung To¹, King Yee Ying², Cheuk-Wan Yim³ and Woon Leung Ng⁴, ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Department of Medicine, Princess Margaret Hospital, Hong Kong, Hong Kong, ³Dept of Medicine, United Christian Hospital, Hong Kong, Hong Kong, ⁴Medicine, United Christian Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the risk factors for renal function decline in patients with lupus nephritis treated initially with combined steroid and MMF or Tac.Methods: Data…
Abstract Number: 601 • 2013 ACR/ARHP Annual Meeting
Hypovitaminosis D and The Metabolic Syndrome In Patients With Systemic Lupus Erythematosus (SLE)
Chi Chiu Mok¹, Ling Yin Ho¹ and Daniel Birmingham², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Medicine, Ohio State University Medical Center, Columbus, OH
Background/Purpose: Low vitamin D level has been linked to cardiovascular diseases and mortality in the general population. Hypovitaminosis D is associated with certain traditional vascular…
Abstract Number: 574 • 2013 ACR/ARHP Annual Meeting
Oral Candidiasis in Systemic Lupus Erythematosus
Monthida Fangtham, Hong Fang and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Candida is the most common opportunistic fungal infection identified in SLE. In a previous autopsy study, 14 percent of deaths in SLE patients were…
Abstract Number: 579 • 2013 ACR/ARHP Annual Meeting
Switching Treatment Between Mycophenolate Mofetil and Azathioprine In Lupus Patients The Reasons and The Effect
Hesham Al Maimouni, Dafna D. Gladman, Dominique Ibanez and Murray B. Urowitz, Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Disease activity in systemic lupus erythematosus is an important predictor of subsequent organ damage and mortality from lupus. However, the optimal agent for chronic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].